Year: 2020

ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) — Paya, a leading integrated payments and commerce solution provider, today announced that Jeff Hack, Paya CEO and other senior management team members are scheduled to participate in the following upcoming virtual investor conferences:Citi Financial Technology Virtual ConferenceDate: Wednesday, November 18, 2020Credit Suisse 24thAnnual Technology ConferenceDate: Monday, November 30, 2020Presentation time: 3:00pm ESTRaymond James Technology Investors ConferenceDate: Monday, December 7, 2020Presentation time: 4:10pm ESTThe presentations will be webcast live, and replays will be available for a limited time under the “Events & Presentations” section on the Company’s investor relations website at investors.paya.com.About PayaPaya is a leading provider of integrated payment and frictionless...

        Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian CancerContinues Following Patients for Overall Survival in Phase III OPTIMA StudyConference Call Begins Today at 11:00 a.m. Eastern TimeLAWRENCEVILLE, N.J, Nov. 16, 2020 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three and nine months ended September 30, 2020, and provided an update on clinical development programs with GEN-1, its DNA-mediated IL-12 immunotherapy currently in Phase II development for the treatment of advanced ovarian cancer, and ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin currently in Phase III development for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer.“The OVATION 2 Study with our GEN-1...

FLORHAM PARK, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 10,828,364 titled “Method for Reducing a Myeloid Derived Suppressor Cell Population With Cationic Lipid Vaccine Compositions” by the United States Patent and Trademark Office (USPTO).“The award of this patent provides broad protections for our Versamune® platform,” commented Dr. Frank Bedu-Addo, CEO of PDS Biotech. “Today, there are three active mid-stage clinical trials of our lead program, PDS0101 partnered with leaders in immuno-oncology, and we believe that the Versamune® platform may provide improved...

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Event on Tuesday, December 8, 2020, from 9:00 a.m. to approximately 11:30 a.m. EST.The event, to be held virtually, will include presentations from Syneos Health leadership about the Company’s unique product development model and plan to drive accelerated growth in the evolving healthcare environment.A live webcast, including audio, video, presentation materials and an archived replay, will be available on the Company’s Investor Relations website at investor.syneoshealth.com. Participants can pre-register and also access the webcast directly at SyneosHealthInvestorDay.com.About...

MIAMI, Nov. 16, 2020 (GLOBE NEWSWIRE) — via InvestorWire – Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multichannel environment including point of sale (“POS”), e-commerce and mobile devices, today reports its financial results for the third quarter ended Sept. 30, 2020.Third Quarter 2020 Financial ResultsTotal transaction volume increased to $956.2 million, as compared to $953.7 million for the same comparable period in 2019.Net revenues decreased to $16.7 million, as compared to $16.8 million for the same comparable period in 2019.North American Transaction Solutions revenue increased to $16.07 million, as compared to $15.9 million for the same comparable period in 2019.International Transaction Solutions...

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — Logiq, Inc. (OTCQX: LGIQ) (formerly Weyland Tech), a global provider of award-winning eCommerce and Fintech solutions, reported results for the three and nine months ended September 30, 2020. All quarterly and nine-month comparisons are to the same year-ago period unless otherwise noted.Financial HighlightsRevenue in Q3 totaled $7.0 million, declining 22% primarily due to the impact of the COVID-19 pandemic on SMB customers using the company’s AppLogiq mobile app platform-as-as-service, which was partially offset by increased revenue from DataLogiq consumer data management platforms.Revenue for the nine months ended September 30, 2020 increased 27% to $31.3 million.Consolidated gross profit for the first nine months of 2020 increased 14% to $5.0 million or 15.9% of consolidated revenue.Cash...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to raise awareness of the importance of timely diagnosis of systemic lupus erythematosus (SLE), the most common and severe form of lupus. At the center of the program are the proprietary AVISE® laboratory tests, which can facilitate early diagnosis and management of SLE, a complex, incurable autoimmune disease. The details of the agreement are confidential.This extension follows a similar one-year extension...